INDIANAPOLIS, U.S., Aug 28, 2026
Roche has received U.S. FDA clearance for Elecsys® Phospho-Tau (217P) Plasma (pTau217), a blood-based biomarker test designed to aid the assessment of amyloid pathology associated with Alzheimer’s disease. Developed in collaboration with Eli Lilly and Company, the test is intended for individuals 55 years and older who have signs, symptoms, or complaints of cognitive decline. Roche said the assay is the first and only FDA-cleared single-biomarker blood test designed to support both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings.
Single-Biomarker Test Expands Alzheimer’s Assessment
The FDA clearance provides clinicians with a minimally invasive blood-based option that can be incorporated into the Alzheimer’s diagnostic pathway. Elecsys pTau217 generates positive, intermediate, or negative results to help assess the likelihood of amyloid pathology, with results interpreted alongside clinical information and other relevant findings rather than used as a stand-alone diagnosis. The test uses the same validated clinical cutoffs across primary and specialty care, potentially helping standardize assessment between different healthcare settings. The availability of a blood-based biomarker could address several limitations associated with traditional amyloid assessment methods. PET imaging and cerebrospinal fluid testing can be costly, invasive, or difficult to access outside specialist centers. Roche said Elecsys pTau217 may help clinicians identify patients with a higher or lower likelihood of amyloid pathology and determine which individuals may benefit from additional evaluation, specialist referral, PET imaging, or CSF testing.
Roche Targets Earlier, More Accessible Diagnosis
The new test is designed for use in people aged 55 years and older experiencing cognitive decline associated with Alzheimer’s disease. In clinical evaluation, Elecsys pTau217 demonstrated high agreement with amyloid PET imaging, supporting its potential role as a blood-based tool for assessing amyloid pathology. Roche describes the approach as its “Power of One” strategy, combining one assay, one biomarker, and one set of validated clinical cutoffs to simplify laboratory implementation. The diagnostic advance comes against a substantial unmet need in dementia care. Roche cited estimates that approximately 75% of people living with dementia remain undiagnosed, while patients who receive a diagnosis may experience prolonged uncertainty after symptoms begin. By bringing amyloid assessment into a blood test, the company aims to support earlier evaluation and potentially improve the efficiency of diagnostic pathways for patients and healthcare providers.
Advertisement
Existing Roche Infrastructure Supports Deployment
A key implementation advantage is the assay’s compatibility with Roche’s existing laboratory infrastructure. Elecsys pTau217 is designed for use across more than 4,500 Roche cobas® laboratory instruments installed in U.S. clinical laboratories, meaning healthcare systems may be able to implement the test without requiring additional instrumentation. Roche said this installed base could support broad access and integration into existing laboratory workflows following FDA clearance. The clearance also strengthens Roche’s broader Alzheimer’s disease diagnostics and therapeutics strategy. Its portfolio includes additional Elecsys neurology assays and research-use-only biomarker tests, alongside investigational medicines including trontinemab and nivegacetor. The company said the combination of diagnostic technologies and medicines reflects its strategy to advance both earlier Alzheimer’s diagnosis and treatment. Importantly, Roche states that Elecsys pTau217 is not intended to be used as a stand-alone test, and its results should be interpreted with other diagnostic tools and clinical information. The FDA clearance nevertheless marks a significant development for blood-based Alzheimer’s biomarkers, potentially expanding access to amyloid assessment across primary and specialty care.
Source: Roche press release
